Moderna earnings release, July 31, 2026

Moderna, Inc. (MRNA) · Form 8-K, Item 2.02 · Filed · SEC filing

Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates

Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97)

Reiterates plan to deliver up to 10% revenue growth in 2026

Improves 2026 GAAP operating expense outlook by approximately $0.2 billion from previous estimate and improves expected 2026 year-end cash balance to $4.7 - 5.2 billion

Anticipates potential approval of Moderna's fifth product with the August 5th PDUFA date for mFLUSIVA, the Company's seasonal influenza vaccine candidate

Announces that mRNA-1403, Moderna’s norovirus vaccine candidate, did not meet statistical criteria for early success at the Phase 3 interim analysis and the Company is preparing to enroll an additional cohort

CAMBRIDGE, MA / ACCESSWIRE / July 31, 2026 /

Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2026.

"The second quarter marked another period of strong execution for Moderna as we advanced our pipeline and strengthened our financial profile with an improved 2026 operating expense outlook," said Stéphane Bancel, Chief Executive Officer of Moderna. "In the second half of 2026, we are preparing for the potential approval of mFLUSIVA in the U.S., which would be our fifth approved product, and continue to anticipate important pivotal readouts for our intismeran in melanoma and propionic acidemia programs."

Commercial Updates

During the second quarter, Moderna continued to advance its multi-year revenue growth strategy by executing on strategic partnerships and key approvals. In Brazil, a collaboration was signed with a local manufacturer in support of a supply agreement for COVID vaccines. In the EU, the Company signed a joint procurement contract with the European Commission on behalf of six countries for up to 24 million doses of mRESVIA®.

Moderna also received regulatory approvals in Australia and Mexico for mRESVIA and in Japan and Taiwan for mNEXSPIKE®, and its investigational seasonal influenza vaccine, mFLUSIVA®, received a unanimous recommendation from the Vaccines and Related Biological Products Advisory Committee (VRBPAC) ahead of an August 5 Prescription Drug User Fee Act (PDUFA) goal date in the U.S.

Second Quarter 2026 Financial Results

Revenue

: Total revenue for the second quarter of 2026 was $145 million, compared to $142 million in the same period in 2025. Lower COVID vaccine sales in the U.S. and South America were offset by deliveries in the United Kingdom under a long-term strategic government partnership and higher¹ stand-ready manufacturing and collaboration revenue. Revenue was $87 million in the U.S. and $58 million in international markets.

Cost of Sales:

Cost of sales for the second quarter of 2026 was $93 million, including $41 million of inventory write-downs, $23 million of unutilized manufacturing capacity costs, and $11 million of third-party royalties. Cost of sales decreased by 22% compared to the same period in 2025, primarily reflecting lower unutilized manufacturing capacity costs resulting from continued manufacturing productivity improvements and operational efficiencies.

Research and Development Expenses:

Research and development expenses for the second quarter of 2026 were $651 million, a 7% decrease compared to the same period in 2025. The decrease was primarily driven by lower clinical development costs following the wind-down of several late-stage programs.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses for the second quarter of 2026 were $216 million, a 6% decrease compared to the same period in 2025. The decrease reflected continued discipline across the organization.

Income Taxes:

Income tax provisions for both periods were not material, as the Company continues to maintain a global valuation allowance against most of its deferred tax assets.

Net Loss:

Net loss was $(0.8) billion for the second quarter of 2026, an improvement of $43 million, or 5%, compared to the second quarter of 2025.

Loss Per Share:

Loss per share was $(1.97) for the second quarter of 2026, compared to loss per share of $(2.13) for the second quarter of 2025.

Cash Position:

Cash, cash equivalents and investments as of June 30, 2026, were $6.9 billion, compared to $7.5 billion as of March 31, 2026. The decrease primarily reflected cash used to fund operations, continued investment in research and development and advancement of the Company’s pipeline. The Company subsequently paid $950 million in July 2026 related to the litigation settlement announced in the first quarter of 2026.

2026 Financial Framework

Revenue:

The Company is targeting up to 10% growth from 2025 revenue and expects 2026 revenue split to be approximately 50% U.S. and approximately 50% international. Moderna expects approximately 55% of its second half 2026 revenue to be recognized in the third quarter.

Cost of Sales:

Cost of sales for 2026 is expected to be approximately $1.7 billion, lowered from approximately $1.8 billion, and including the $0.9 billion non-recurring litigation settlement charge.

Research and Development Expenses:

Research and development expenses for 2026 are now anticipated to be approximately $2.9 billion, lowered from approximately $3.0 billion.

Selling, General and Administrative Expenses:

Selling, general and administrative expenses for 2026 are projected to be approximately $1.0 billion.²

Income Taxes:

The Company expects its full-year tax expense to be negligible.

Capital Expenditures:

Capital expenditures for 2026 are expected to be $0.2 to $0.3 billion.

Cash and Investments:

Year-end cash and investments for 2026 are now projected to be $4.7 to $5.2 billion, an improvement of approximately $0.2 billion. This excludes any further drawdowns from the Company's remaining $0.9 billion available under its credit facility.... (truncated)e Milestones

Infectious disease vaccines:

• Seasonal flu + COVID vaccine

: Moderna has received European Commission marketing authorization for mCOMBRIAX in the EU and its mRNA-1083 regulatory filings are under review in Japan, Canada and Australia. The Company is awaiting further guidance from the U.S. FDA on refiling the submission for its flu plus COVID combination vaccine.

• Seasonal flu vaccine

: The Company's mRNA-1010 regulatory filings are under review in Europe, Canada and Australia and potential approvals are expected to begin in 2026. The U.S. FDA has assigned a PDUFA date for mRNA-1010 of August 5, 2026.

• Norovirus vaccine

: Moderna's Phase 3 safety and efficacy study of mRNA-1403 did not meet statistical criteria for early success at the Phase 3 interim analysis. The trial is ongoing and remains blinded as the Company works toward enrolling an additional cohort.

Oncology therapeutics:

• Intismeran autogene

: The Company is advancing mRNA-4157 in collaboration with Merck, with nine total Phase 2 and Phase 3 clinical trials underway across multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), bladder cancer and renal cell carcinoma. This includes the

Phase 3 study of intismeran as monotherapy and in combination with KEYTRUDA QLEX for the treatment of high-risk Stage 1 NSCLC announced last quarter.

Fully enrolled studies include a Phase 3 adjuvant melanoma, a Phase 2 adjuvant renal cell carcinoma, and a Phase 2 adjuvant muscle invasive bladder cancer. Moderna expects Phase 3 adjuvant melanoma data potentially in 2026.

The Company recently presented positive five-year Phase 2b adjuvant melanoma data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which showed a sustained benefit with intismeran in combination with KEYTRUDA, reducing the risk of recurrence or death by 49% compared to KEYTRUDA alone.

• mRNA-4359

: Moderna's Phase 1/2 study of mRNA-4359, an investigational wholly-owned cancer antigen therapy, is ongoing. The Phase 2 portion of the study includes cohorts in first-line metastatic melanoma, second-line+ metastatic melanoma and first-line metastatic NSCLC.

Rare dise ase therapeutics:³

• Propionic acidemia (PA) therapeutic

: The Company's PA candidate, mRNA-3927, is in a registrational study and target enrollment has been reached. Moderna expects potential data in 2026.

• Methylmalonic acidemia (MMA) therapeutic

: The Company deferred its decision on a pivotal trial for mRNA-3705 until PA registrational data readout.

Moderna Corporate Updates

• Appointed Ester Banque to Chief Commercial Officer of Moderna, effective June 15, 2026.

• Appointed Michael McDonnell, former Chief Financial Officer of Biogen, to Moderna's Board of Directors, effective July 8, 2026.

Company Accolades

• Moderna was ranked no. 1 by

TIME on its list of the World's Most Impactful Companies.

Key 2026 Investor and Analyst Event Dates

• Analyst Day: November 12

Investor Call and Webcast Information

Moderna will host a live conference call and webcast at 8:00 a.m. ET on July 31, 2026. To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers and a unique pin number will be provided. A live webcast of the call will also be available under "Events and Presentations" in the Investors section of the Moderna website.

• Telephone: https://register-conf.media-server.com/register/BI9a3abdd346bd413a90a4701513c4ca38

• Webcast: https://investors.modernatx.com

The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.⁴

Financial statements

Income Statement

Three Months Ended June 30, — (Unaudited, in millions, except per share data)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue:Net product sales94114446200
Revenue:Other revenue151288850
Revenue:Total revenue145142534250
Operating expenses:Cost of sales931191,048209
Operating expenses:Research and development6517001,3001,556
Operating expenses:Selling, general and administrative216230389442
Operating expenses:Total operating expenses9601,0492,7372,207
Operating expenses:Loss from operations-815-907-2,203-1,957
Operating expenses:Interest income6781139171
Operating expenses:Other (expense) income, net-198-374
Operating expenses:Loss before income taxes-767-818-2,101-1,782
Operating expenses:Provision for income taxes1572414
Operating expenses:Net loss-782-825-2,125-1,796
Net loss per shareBasic and Diluted-1.97-2.13-5.36-4.64
Weighted average common shares used in calculation of net loss per shareBasic and Diluted398388396387

Balance Sheet

December 31, — (Unaudited, in millions)

June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents1,7232,595
Current assets:Investments3,4153,204
Current assets:Accounts receivable, net17184
Current assets:Inventory280153
Current assets:Prepaid expenses and other current assets380408
Current assets:Total current assets5,8156,544
Current assets:Investments, non-current1,7722,336
Current assets:Property, plant and equipment, net2,0592,134
Current assets:Right-of-use assets, operating leases697719
Current assets:Other non-current assets618605
Current assets:Total assets10,96112,338
Current liabilities:Accounts payable167317
Current liabilities:Accrued liabilities1,9091,386
Current liabilities:Deferred revenue29599
Current liabilities:Other current liabilities163185
Current liabilities:Total current liabilities2,5341,987
Current liabilities:Deferred revenue, non-current147153
Current liabilities:Operating lease liabilities, non-current638653
Current liabilities:Financing lease liabilities, non-current620
Current liabilities:Long-term debt591590
Current liabilities:Other non-current liabilities284285
Current liabilities:Total liabilities4,2003,688
Stockholders’ equity:Additional paid-in capital1,6441,382
Stockholders’ equity:Accumulated other comprehensive income1945
Stockholders’ equity:Retained earnings5,0987,223
Stockholders’ equity:Total stockholders’ equity6,7618,650
Stockholders’ equity:Total liabilities and stockholders’ equity10,96112,338

Cash Flow

Six Months Ended June 30, — (Unaudited, in millions)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating activitiesNet loss-2,125-1,796
Adjustments to reconcile net loss to net cash used in operating activities:Stock-based compensation224245
Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization12296
Adjustments to reconcile net loss to net cash used in operating activities:Amortization/accretion of investments-21-37
Adjustments to reconcile net loss to net cash used in operating activities:Loss on equity investments, net28
Adjustments to reconcile net loss to net cash used in operating activities:Other non-cash items1036
Changes in assets and liabilities:Accounts receivable, net167310
Changes in assets and liabilities:Prepaid expenses and other assets70-150
Changes in assets and liabilities:Inventory-126-122
Changes in assets and liabilities:Right-of-use assets, operating leases2119
Changes in assets and liabilities:Accounts payable-128-203
Changes in assets and liabilities:Accrued liabilities475-395
Changes in assets and liabilities:Deferred revenue19568
Changes in assets and liabilities:Operating lease liabilities-15-10
Changes in assets and liabilities:Other liabilities-27-25
Changes in assets and liabilities:Net cash used in operating activities-1,156-1,956
Investing activitiesPurchases of marketable securities-1,904-3,059
Investing activitiesProceeds from maturities of marketable securities1,4423,424
Investing activitiesProceeds from sales of marketable securities8141,059
Investing activitiesPurchases of property, plant and equipment-99-120
Investing activitiesPurchase of intangible asset-10
Investing activitiesNet cash (used in) provided by investing activities2531,294
Financing activitiesProceeds from issuance of common stock through equity plans4217
Financing activitiesTax payments related to net share settlements on equity awards-4-1
Financing activitiesChanges in financing lease liabilities-7-3
Financing activitiesNet cash provided by financing activities3113
Financing activitiesEffect of changes in exchange rates on cash and cash equivalents-11
Financing activitiesNet decrease in cash, cash equivalents and restricted cash-873-648
Financing activitiesCash, cash equivalents and restricted cash, beginning of year2,5971,929
Financing activitiesCash, cash equivalents and restricted cash, end of period1,7241,281

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Moderna earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.